Overview of Proteasome Inhibitor-Based Anti-cancer Therapies: Perspective on Bortezomib and Second Generation Proteasome Inhibitors versus Future Generation Inhibitors of Ubiquitin-Proteasome System

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|14|6|517-536

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.14, Iss.6, 2014-07, pp. : 517-536

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The ubiquitin–proteasome system and assays to determine responses to inhibitors

By Tsvetkov Lyuben   Nanjundan Meera   Domino Maria   Daniel Kenyon G  

Expert Opinion on Drug Discovery, Vol. 5, Iss. 12, 2010-12 ,pp. : 1221-1236

Informa Healthcare

Access to resources Recommend Favorite

The Ubiquitin-Proteasome System (UPS) and the Mechanism of Action of Bortezomib

By  

Current Pharmaceutical Design, Vol. 17, Iss. 15, 2011-05 ,pp. : 1483-1499

Bentham Science Publishers

Access to resources Recommend Favorite

Second Generation Proteasome Inhibitors: Carfilzomib and Immunoproteasome-Specific Inhibitors (IPSIs)

By  

Current Cancer Drug Targets, Vol. 11, Iss. 3, 2011-03 ,pp. : 285-295

Bentham Science Publishers

Access to resources Recommend Favorite

Editorial (Thematic Issue: Recent Advances in Proteasome Inhibitor-Based Cancer Therapies)

By  

Current Cancer Drug Targets, Vol. 14, Iss. 6, 2014-07 ,pp. : 505-505

Bentham Science Publishers

Access to resources Recommend Favorite

Natural Product Inhibitors of the Ubiquitin-Proteasome Pathway

By  

Current Drug Targets, Vol. 12, Iss. 11, 2011-10 ,pp. : 1581-1594

Bentham Science Publishers

Access to resources Recommend Favorite